Methallenestril
- G03CB03 (WHO)
G03CC03 (WHO)
- 3-(6-Methoxynaphthalen-2-yl)-2,2-dimethylpentanoic acid
- 517-18-0
- 10599
- 10154
- XL025389JS
- DTXSID7023275
- Interactive image
- CCC(c1ccc2cc(OC)ccc2c1)C(C)(C)C(=O)O
- InChI=1S/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)
- Key:KHLJKRBMZVNZOC-UHFFFAOYSA-N
Methallenestril (INNTooltip International Nonproprietary Name) (brand names Cur-men, Ercostrol, Geklimon, Novestrine, Vallestril), also known as methallenoestril (BANTooltip British Approved Name) and as methallenestrol, as well as Horeau's acid,[1][2] is a synthetic nonsteroidal estrogen and a derivative of allenolic acid and allenestrol (specifically, a methyl ether of it) that was formerly used to treat menstrual issues but is now no longer marketed.[3][4][5][6] It is a seco-analogue of bisdehydrodoisynolic acid, and although methallenestril is potently estrogenic in rats, in humans it is only weakly so in comparison.[7] Vallestril was a brand of methallenestril issued by G. D. Searle & Company in the 1950s.[8] Methallenestril is taken by mouth.[9] By the oral route, a dose of 25 mg methallenestril is approximately equivalent to 1 mg diethylstilbestrol, 4 mg dienestrol, 20 mg hexestrol, 25 mg estrone, 2.5 mg conjugated estrogens, and 0.05 mg ethinylestradiol.[9]
See also
References
- ^ Heftmann E (1970). Steroid Biochemistry. Academic Press. p. 144. ISBN 9780123366504.
- ^ Dodds EC (March 1949). "Synthetic oestrogens". The Journal of Pharmacy and Pharmacology. 1 (3): 137–147. doi:10.1111/j.2042-7158.1949.tb12391.x. PMID 18114509. S2CID 221921908.
- ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1295–. ISBN 978-0-412-46630-4.
- ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 177–. ISBN 978-94-011-4439-1.
- ^ Thomas JA, Keenan EJ (1986). "Estrogens and Estrogenic Compounds". Principles of Endocrine Pharmacology. Springer Science & Business Media. p. 136. ISBN 978-1-4684-5036-1.
- ^ Herbai G, Ljunghall S (1983). "Normalization of hypercalcaemia of primary hyperparathyroidism by treatment with methallenestril, a synthetic oestrogen with low oestrogenicity". Urologia Internationalis. 38 (6): 371–373. doi:10.1159/000280925. PMID 6659184.
- ^ Kirk RE, Othmer DF (1980). Encyclopedia of chemical technology. Wiley. p. 670. ISBN 978-0-471-02065-3.
- ^ Catalog of Copyright Entries: Third Series. Vol. 17. Copyright Office, Library of Congress. July–December 1963. pp. 1984–.
- ^ a b Swyer GI (April 1959). "The oestrogens". British Medical Journal. 1 (5128): 1029–1031. doi:10.1136/bmj.1.5128.1029. PMC 1993181. PMID 13638626.
- v
- t
- e
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Estrogen receptor modulators
- Androgens and antiandrogens
- Progestogens and antiprogestogens
- List of estrogens
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e